Vioxx has an indication for treatment of acute pain; Celebrex does not -- it has been approved for the treatment of rheumatoid arthritis and osteoarthritis.
The supplements are marketed as treatments for osteoarthritis, the degenerative joint disease that afflicts about 21 million people nationwide.
Arthritis researchers say they're finally beginning to understand how to attack the most common form of the disabling disease, called osteoarthritis -- the deterioration of the cartilage that cushions each joint, generally causing symptoms after age 45.
Currently, 23 million Americans suffer from osteoarthritis -- one in every eight adults.
Pain sufferers may be getting some new drug options that appear to bring relief with fewer side effects than most other treatments.
The early results of research, including one study just published and another due out soon, suggest the treatment actually does ease joint pain and may even forestall further cartilage damage.
The largest of its kind, published this month in the journal Osteoarthritis and Cartilage, looked at how glucosamine-chondroitin affected pain and movement in 93 patients with arthritic knees.
``The treatment was significantly more effective than a placebo for pain and function,'' said Dr. Amal Das, a joint replacement surgeon in Hendersonville, N.C., and the lead author.
That finding is consistent with reports from private physicians nationwide and with the results of other, smaller studies, including one published last year involving 34 Navy personnel suffering from knee or lower back pain.
A new study raises questions about how useful the vitamin can be in helping
